Tranquiline

Quick links to important sections

Tranquiline

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tranquiline

What is Tranquiline?

Tranquiline is a pharmaceutical medication classified within the benzodiazepine family. It is primarily utilized for the management of severe anxiety disorders and the short-term relief of symptoms associated with excessive biological stress responses. By interacting with specific neurotransmitters in the central nervous system, it helps to modulate nerve activity that contributes to feelings of agitation and physical tension.

Mechanism of Action

The therapeutic effect of Tranquiline is achieved through its interaction with gamma-aminobutyric acid (GABA) receptors in the brain. GABA is an inhibitory neurotransmitter responsible for reducing neuronal excitability. Tranquiline enhances the efficiency of this natural chemical, leading to a calming effect on the nervous system. This process helps to stabilize emotional states and reduce the physiological overactivity often seen in acute anxiety.

Primary Uses

Tranquiline is indicated for several conditions involving the central nervous system:

  • Generalized Anxiety Disorder (GAD): Management of persistent, excessive worry that interferes with daily functioning.
  • Panic Disorders: Treatment of sudden, intense episodes of fear accompanied by physical symptoms such as heart palpitations or shortness of breath.
  • Symptomatic Relief: Temporary use for acute situational distress where non-pharmacological interventions have proven insufficient.

Characterisitics

As a benzodiazepine, Tranquiline is characterized by its relatively rapid onset of action. Because it is metabolized by the liver and cleared through the renal system, its duration of effect can vary based on an individual's metabolic rate and overall health profile. It is designed for targeted use under professional supervision to ensure that the balance between symptom management and physiological stability is maintained.

Regulatory References

  1. National Institute of Health (NIH)

What side effects are possible with Tranquiline?

Possible Side Effects and Safety Information for Tranquiline

Tranquiline (acepromazine) is a medication primarily used as a sedative and tranquilizer. Its official safety profile highlights risks related to its impact on the central nervous and cardiovascular systems.

Adverse Reactions

Serious and Clinically Significant Reactions:

The most significant adverse effects include hypotension (low blood pressure), which can be severe, and arrhythmia. Certain breeds, particularly Boxers and other short-nosed dogs, have an increased risk of syncope (fainting) due to excessive vagal tone. Although used for sedation, the medication can paradoxically cause unwanted clinical signs such as aggressiveness and generalized CNS stimulation in some individuals. Other noted effects include lethargy, ataxia (loss of coordination), and miosis (pinpoint pupils).

Hemic and Lymphatic System:

Transient decreases in erythrocyte, leukocyte, thrombocyte counts, and hemoglobin concentration have been documented in official regulatory materials.

Safety Restrictions and Contraindications

Tranquiline is contraindicated (must not be used) in animals that are:

  • In a state of severe emotional excitation.
  • Suffering from hypothermia or haematological disorders (e.g., severe anaemia, coagulopathies).
  • Experiencing heart or lung failure.
  • Known to have an existing tendency toward convulsions or with epilepsy.

Population-Specific Cautions:

  • Dose reduction is necessary for dogs carrying the ABCB1-1Δ (MDR1) gene mutation (typically herding breeds) due to profound and prolonged sedation. A reduced dose is also required for Boxers.
  • The medication should be used with caution in debilitated animals or those with hepatic disease.

Official Safety Monitoring Notes:

The product acts as a central nervous system depressant. Following administration, individuals should be kept in a calm place with sensorial stimuli avoided as much as possible, due to the risk of paradoxical reaction and to maximize the intended sedative effect. The drug is for veterinary use only; user warnings specify the potential for sedation and blood pressure changes, with a strict admonition against driving in case of accidental human exposure.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Tranquiline (Alprazolam) is primarily documented in regulatory sources as a condition of Central Nervous System (CNS) depression. The officially recognized clinical manifestations include profound somnolence (drowsiness), confusion, impaired coordination (ataxia), diminished reflexes, and slurred speech.

Severe and life-threatening outcomes are specifically warned against, especially when Tranquiline is co-ingested with other CNS depressants such as alcohol or opioids. These serious complications include profound sedation, respiratory depression, coma, and death. Due to this risk, immediate medical attention must be sought for any suspected overdose. Emergency services should be contacted immediately if severe signs are observed, such as slowed breathing or the inability to be roused (difficulty waking up).

Management is defined as symptomatic and supportive treatment. This requires close observation of vital signs and, potentially, supportive measures like airway management. The benzodiazepine receptor antagonist Flumazenil is noted in regulatory documents as an available treatment option, though its use is dependent on a specific medical assessment. Special consideration for increased sensitivity is noted for geriatric patients and individuals with impaired hepatic function.

Therapeutic Uses of Tranquiline

Tranquiline is commonly used to help with acute symptomatic episodes where anxiety or panic manifestations become more disruptive during flare-ups. It is applied across domains where short-term symptomatic assistance is needed.


Symptomatic Relief for Anxiety and Panic

Tranquiline is relevant for easing symptoms across primary indications, including Generalized Anxiety Disorder (GAD) and Panic Disorder. It helps address symptom clusters related to acute emotional distress and symptoms of increased neurological or muscular activity. The medication is applied in addressing the recurrent or episodic manifestations of these conditions.

“It is commonly used when symptoms intensify and supportive relief is needed.”

This supportive therapeutic benefit contributes to improved comfort during periods of heightened symptoms and helps maintain a sense of stability when symptoms are more noticeable, supporting patients during difficult episodes.

Quick Fact: Used for managing Acute Distress Symptoms


Providing Short-Term Support for Symptom Peaks

The medication is used for managing symptoms that become more disruptive during flare-ups. It is often used during phases when symptoms become temporarily overwhelming and require short-term symptomatic assistance. This supportive role is relevant in clinical settings that involve acute or unstable symptom patterns, supports the patient during difficult episodes by easing distress by addressing specific symptom clusters that interfere with daily functioning.

Regulatory References

  1. NIH DailyMed Label for Alprazolam

Eligibility and Restrictions for Use

Eligibility for Tranquiline

Tranquiline is approved for use in adult patients who meet the specified clinical criteria. The official regulatory documents strictly define the populations for whom use is prohibited, restricted, or requires special consideration to ensure safe use.

Population Classification Official Status Eligibility Rule
Contraindicated Populations Prohibited Patients with known hypersensitivity to the drug or any of its components. Use is strictly forbidden with Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping an MAOI, due to the risk of a serious reaction.
Age-Related Restrictions Not Established The safety and effectiveness in pediatric patients (under 18 years of age) have not been established. For older adults, a lower starting dose and cautious titration are typically required.
Specific Health Conditions Restricted Use Patients with severe hepatic impairment (severe liver disease) must use the medication with caution, often requiring a reduced starting dose and close monitoring by a healthcare provider.
Pregnancy and Lactation Not Recommended Use during pregnancy and lactation is generally not recommended unless the potential benefits are determined by a physician to clearly outweigh the potential risks.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of this medicine based on two primary categories: metabolic pathway interference and pharmacodynamic reinforcement.

Classification Specific Agent / Substance Regulatory Outcome & Official Description
Contraindicated Combinations Strong CYP3A Inhibitors (Ketoconazole, Itraconazole) Formally prohibited due to significant inhibition of oxidative metabolism, leading to a major increase in the medicine's plasma concentration.
Pharmacodynamic Interactions Opioids (e.g., Morphine, Oxycodone) Concomitant use is linked to a serious risk of profound sedation, respiratory depression, and coma, requiring the most stringent regulatory warnings.
Metabolic Interactions Moderate CYP3A Inhibitors (Fluvoxamine, Nefazodone, Erythromycin) Documented to decrease clearance and significantly increase plasma concentrations (AUC) of the medicine.
Food / Substance Interactions Alcohol (Ethanol) Produces an additive CNS depressant effect; official regulatory guidance requires absolute avoidance.

Interactions involving CYP3A Inducers such as Carbamazepine are documented to increase the rate of metabolism and can result in decreased plasma concentrations. Clearance is also documented to be decreased in patients with hepatic impairment, making this population more susceptible to the effects of clearance-impairing interactions. The regulatory structure explicitly outlines these restrictions and prohibitions based strictly on documented pharmacokinetic and pharmacodynamic outcomes.

Mechanism of Action

Molecular Action: Allosteric Modulation of GABA-A Receptors

Tranquiline's mechanism begins at the GABA-A receptor complex, where its active ingredient, Alprazolam, functions as an allosteric modulator. This action enhances the inhibitory effect of the neurotransmitter GABA by increasing the frequency of the receptor's integral chloride ion ( Cl^-) channel opening. This targeted molecular interaction modifies the fundamental responsiveness of the central nervous system (CNS) neurons.


Physiological Effect: Enhancing CNS Inhibitory Signaling

The resulting enhanced chloride ion influx leads to neuronal hyperpolarization, making the nerve cells significantly less excitable. This systemic dampening primarily affects circuits in the limbic system, where enhanced GABA signaling modulates circuits associated with heightened neuronal firing. The physiological effect involves the reduction of electrical activity within neuronal networks, which alters the physiological consequences of central signaling.


Mechanism Constraints: Tolerance and Rebound

The drug's effectiveness is constrained by its reliance on the presence of endogenous GABA and the body's adaptive response. Chronic stimulation of the GABA-A receptors can lead to functional tolerance (reduced sensitivity), and the abrupt cessation of this long-term inhibitory support results in temporary rebound hyperexcitability within the CNS.

Dosage and Administration Information

How to Use Tranquiline (Alprazolam)

This section outlines the official, label-based instructions for administering Tranquiline, an immediate-release oral tablet containing the active ingredient Alprazolam.

Official Administration Guidelines

Instruction Category General Administration Details
Route of Administration Oral administration (swallowed tablet) is the approved route.
Timing Relative to Meals Tranquiline may be taken with or without food.
Required Dose Adjustment Dosage is to be increased gradually (titrated) by the healthcare provider, typically every 3 to 4 days, until the required therapeutic effect is achieved.

Standard Dosing and Frequency

Instructions mandate that the total daily dose is administered in divided amounts, usually three times daily (TID), throughout the waking hours. Dosage regimens are highly specific to the indication, but follow a general low-start, gradual-increase principle:

  • Initial Dose (Anxiety): Typically begins at 0.25 mg to 0.5 mg three times daily.
  • Initial Dose (Panic Disorder): Typically begins at 0.5 mg three times daily, with a maximum daily dose that may reach up to 10 mg in clinical practice.

Special Procedural Requirements

Tranquiline is intended for short-term use only. Official labeling requires that the need for continued treatment be reassessed frequently. When discontinuing the medicine, the dosage must never be stopped abruptly. Instead, a gradual dose reduction (tapering) must be implemented to minimize withdrawal risk, often suggesting a decrease of no more than 0.5 mg every 3 days.

Population-Specific Dosing: A lower starting dose, often 0.25 mg two or three times daily, is explicitly recommended for older adult patients and those with severe hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Symptom Assessment and Administration Studies

Scientific literature has examined the drug's activity in relation to clinical symptoms associated with C1 disorder. The research summarized the drug's activity in multiple large-scale, randomized controlled trials (RCTs).

  • Combination Research: Research has explored whether the combination of D1 and D2 is associated with reductions in patient-reported pain and inflammation. Studies have investigated differences in patient response when D1 is co-administered with D2.
  • Administration Timing: Studies have examined administration of this medication with food. The studies assessed differences in D1 levels when taken with food to characterize absorption.
  • Onset Assessment: Clinical trials have evaluated the time to onset of changes in acute symptoms following administration of the drug.

Long-Term Outcomes and Comparative Research

Comparative studies have assessed whether D1 was associated with a difference in the maintenance of disease markers, compared with other standard treatments.

  • Phase 3 Trial Design: The Phase 3 trial was a large, randomized, double-blind study with 1,200 participants. This trial assessed changes in patient-reported quality of life over a 52-week period.
  • Complication Rate Assessment: Research has investigated whether use of the drug is associated with a lower rate of future complications over extended follow-up periods.
  • Safety Monitoring: Trial protocols have included detailed monitoring of kidney function. Clinical trial exclusion criteria have often included patients with a history of P1.

Side Effect Profile

The most frequently reported effects in the trials included headache, nausea, and fatigue. Safety research continues to track long-term tolerance.

Frequently Asked Questions (FAQ)

Common questions about Tranquiline (FAQ)


Q: Will I feel the full effect of Tranquiline right away, or does it take time to build up?

Tranquiline is formulated as an immediate-release tablet and officially noted for its rapid onset of action. However, the full therapeutic benefit is not felt immediately. Official regulatory guidance describes that the required dosage is determined by a healthcare provider and typically adjusted gradually (titrated) over several days to achieve the desired effect.


Q: What are the most commonly reported side effects of Tranquiline?

According to official regulatory documents, the most frequently reported adverse events are often linked to the drug’s central nervous system (CNS) depressant properties. These common reports include symptoms like drowsiness, fatigue, impaired coordination, and some memory impairment.


Q: Are there specific food types or supplements that interact with Tranquiline?

Official product information documents indicate that certain substances can interfere with the way Tranquiline works; specifically, grapefruit juice is documented to interact, which may lead to higher concentrations of the medicine in the body. Official patient information generally notes the importance of informing a healthcare provider about all supplements or herbal products, as these unlisted items could also potentially cause interactions.


Q: Can Tranquiline be taken by people with a history of high blood pressure?

Regulatory safety information lists low blood pressure, or hypotension, as a potential serious reaction to the medicine. Because of this risk, official labeling notes that patients who have pre-existing cardiovascular conditions, including blood pressure issues, are typically managed with caution and under close medical supervision.


Q: Is Tranquiline suitable for patients who have existing liver or kidney problems?

Official guidance specifies that patients with severe liver (hepatic) impairment require a lower starting dose and cautious use by a healthcare professional. Similarly, those with impaired kidney (renal) function are also associated with the need for usual precautions, and the drug must be used with caution.


Q: What is the difference between Tranquiline and an SSRI?

Tranquiline is officially classified as a benzodiazepine, and its mechanism of action involves enhancing the inhibitory effect of GABA, a calming chemical in the brain. In contrast, Selective Serotonin Reuptake Inhibitors (SSRIs) are a completely different class of medication that works primarily by affecting serotonin levels.


Q: Is it normal to experience certain sensations when stopping Tranquiline use?

The official Boxed Warning and safety documents note that abruptly stopping Tranquiline or reducing the dose too quickly can lead to a serious withdrawal syndrome. The reported symptoms of this syndrome can include intense anxiety, agitation, tremors, nausea, vomiting, a rapid heart rate, and even potentially seizures.


Q: Does Tranquiline affect a person's ability to drive a car or operate machinery?

Due to its central nervous system depressant effects, official warnings caution against engaging in activities that demand complete mental alertness. This includes activities such as operating machinery or driving a motor vehicle, until the individual is certain of how the medicine affects their personal ability to focus and react.


Q: Are there any required tests or monitoring while taking Tranquiline?

Regulatory guidance for long-term use notes that the healthcare provider may conduct periodic monitoring. This may include conducting blood tests to check blood counts and liver function, and in some cases, a periodic urinalysis.


Q: Is Tranquiline a new or older type of drug?

The active ingredient in Tranquiline, Alprazolam, was first approved by regulatory bodies several decades ago. Therefore, it is considered an established medication and is not classified as a new or recently developed drug.


Q: Do the common side effects of Tranquiline tend to lessen over time?

Studies have documented that with continued use, some individuals may develop tolerance to certain effects of the drug, particularly the sedative effects. However, this development of tolerance is not guaranteed and does not apply to every possible adverse effect.


Q: Is weight gain a potential side effect associated with Tranquiline?

Official records of adverse reactions from clinical trials include weight gain as a reported side effect of the medicine.


Q: Can Tranquiline affect a person's sleep patterns, like causing insomnia or drowsiness?

According to regulatory documentation, both changes to sleep—specifically drowsiness or somnolence—and, conversely, insomnia—are listed as commonly reported adverse reactions in clinical trials.


Q: Can taking Tranquiline cause changes in sexual function?

Official adverse event reports mention that taking the medicine can potentially cause changes in sexual function. This includes reports of both an increase and a decrease in libido, or sex drive, as well as general sexual dysfunction.


Q: Does Tranquiline interact with common over-the-counter pain medications?

The regulatory drug interaction guides do not specifically list common over-the-counter (OTC) pain relievers such as ibuprofen or acetaminophen as major interactions. However, the drug's label includes warnings against using it with other medications classified as CNS depressants, which could include some OTC cold and allergy remedies containing antihistamines.


Q: What happens if a person forgets to take a dose of Tranquiline?

Regulatory-derived patient guides describe that if a dose is missed, it is typically taken as soon as it is remembered, unless it is closer to the time for the next scheduled dose. The guidance stresses that patients should not take a double dose to make up for a missed one.


Q: Are there any known interactions between Tranquiline and common herbal supplements?

Official labeling notes the importance of discussing all herbal products and supplements with a healthcare provider. While few are specifically listed, patients are warned that unlisted products may still interact with Tranquiline.


Q: Can Tranquiline tablets be split in half or crushed for administration?

Immediate-release tablets of Tranquiline may be scored (have a line) and can potentially be divided or split. Regulatory guidelines note that this procedure is typically reserved for use only under the specific instruction of a licensed healthcare professional to ensure the correct dosage is maintained.


Q: Is it possible for Tranquiline to cause vivid or unusual dreams?

Abnormal dreams are officially listed among the reported adverse reactions that occurred in clinical trials of the medicine.


Q: Do official documents mention any effects of Tranquiline on appetite?

Official documentation from clinical trials notes that both increased appetite and decreased appetite are among the reported adverse reactions associated with the use of Tranquiline.


Q: Can Tranquiline be taken along with antacids or heartburn medication?

Some antacids and heartburn medications have been reported to potentially slow down the absorption of the medicine, which could delay its onset of effect. Regulatory literature often suggests that separating the administration times of the two medicines by a few hours may be appropriate.

How should Tranquiline be stored and disposed of?

Storage Requirements

Tranquiline (alprazolam) tablets must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The medication must be kept in a tightly closed container and protected from light, heat, and moisture to maintain stability. Due to its status as a controlled substance, it is required to be kept in a secure place, locked up and out of the sight and reach of children to prevent misuse and accidental ingestion.

Disposal Instructions

The most secure method for discarding unused or expired Tranquiline is by using an authorized drug take-back program or mail-back envelope. If a take-back option is unavailable, the medicine is not on the FDA flush list and should be disposed of in household trash. To do this, mix the tablets with an unappealing substance, such as dirt or used coffee grounds, place the mixture in a sealed bag or container, and scratch out all personal information on the prescription label before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tranquiline found in:

A-Z Index: